{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:13:14Z","timestamp":1762341194600,"version":"build-2065373602"},"reference-count":144,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T00:00:00Z","timestamp":1541203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcitonin gene\u2010related peptide (CGRP) therapeutics introduce new excitement and possibly yet to be determined distressing discords in the field of Headache Medicine. Growth in knowledge of CGRP in the pathophysiology of migraine introduced CGRP antagonism to headache treatment. Potential adverse effects on the other circulatory and neurovascular diseases have been foremost concerns. Failures in development of gepants and growth in knowledge of monoclonal antibody therapeutics combined to deliver the anti\u2010CGRP monoclonal antibodies (mAbs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Current Situation as of July 2018<\/jats:title>\n                    <jats:p>Erenumab, eptinezumab, fremanezumab, and galcanezumab are approved, submitted to, or preparing for submission at both the European Medicines Agency and the US Food and Drug Administration (FDA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Headache Currents update emanates from a symposium on CGRP and immunology in Headache Medicine, and reviews both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusion<\/jats:title>\n                    <jats:p>Understanding CGRP in Headache Medicine requires information on aspects of the CGRP ligand, cell surface G protein receptor, CGRP receptor specifics, and antagonism by CGRP small and large molecules. Recent reports of CGRP\u2019s high affinity for amylin receptors dictate some attention to this family\u2010related peptide. To better understand potential immunogenic risks and off\u2010target toxicities of the anti\u2010CGRP monoclonal antibodies, this review discusses immunology and CGRP and reviews IgG structure and function, monoclonal antibody production, ligand\u2013antigen\u2013antibody relationships, and clinical CGRP mAb specifics. Upon completion, the reader should better summarize CGRP antagonist fundamentals, recall antibody structure and function, restate therapeutic mAbs attributes, and appraise immunogenic risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13432","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T03:59:16Z","timestamp":1541217556000},"page":"131-150","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["CGRP, Amylin, Immunology, and Headache Medicine"],"prefix":"10.1111","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-5650","authenticated-orcid":false,"given":"Frederick R.","family":"Taylor","sequence":"first","affiliation":[{"name":"University of Minnesota Medical School Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,3]]},"reference":[{"key":"e_1_2_38_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(85)90050-5"},{"key":"e_1_2_38_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_38_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102491011S1102"},{"key":"e_1_2_38_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_2_38_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20605"},{"key":"e_1_2_38_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1995.1505384.x"},{"key":"e_1_2_38_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-009-0112-8"},{"key":"e_1_2_38_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409351807"},{"key":"e_1_2_38_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410395790"},{"key":"e_1_2_38_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1838(99)00024-7"},{"key":"e_1_2_38_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-017-0463-4"},{"key":"e_1_2_38_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/313054a0"},{"key":"e_1_2_38_14_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.24.1.487"},{"key":"e_1_2_38_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133868"},{"key":"e_1_2_38_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285610388343"},{"key":"e_1_2_38_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0156-4"},{"key":"e_1_2_38_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.09.003"},{"key":"e_1_2_38_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01532-1"},{"key":"e_1_2_38_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.23828"},{"key":"e_1_2_38_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00232-3"},{"key":"e_1_2_38_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a6cb72"},{"key":"e_1_2_38_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"e_1_2_38_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410368444"},{"key":"e_1_2_38_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00836.x"},{"key":"e_1_2_38_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030505"},{"issue":"3","key":"e_1_2_38_27_1","first-page":"218","article-title":"The CGRP receptor antagonist olcegepant modulates cortical spreading depression in vivo","volume":"57","author":"Eftekhari S","year":"2017","journal-title":"Headache"},{"key":"e_1_2_38_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13084"},{"key":"e_1_2_38_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13064"},{"key":"e_1_2_38_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.010629"},{"key":"e_1_2_38_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13496"},{"key":"e_1_2_38_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.9662"},{"key":"e_1_2_38_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13077"},{"key":"e_1_2_38_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/298240a0"},{"key":"e_1_2_38_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(86)81338-2"},{"key":"e_1_2_38_36_1","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2002.806"},{"key":"e_1_2_38_37_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124701"},{"key":"e_1_2_38_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.60.3.393"},{"key":"e_1_2_38_39_1","doi-asserted-by":"publisher","DOI":"10.1006\/mcne.1999.0767"},{"key":"e_1_2_38_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X17751352"},{"key":"e_1_2_38_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jemt.1081"},{"key":"e_1_2_38_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.198"},{"key":"e_1_2_38_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12618"},{"key":"e_1_2_38_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(85)90013-8"},{"key":"e_1_2_38_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(88)90018-8"},{"key":"e_1_2_38_46_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.233"},{"key":"e_1_2_38_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.197"},{"key":"e_1_2_38_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C200629200"},{"key":"e_1_2_38_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01633.x"},{"key":"e_1_2_38_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12129"},{"key":"e_1_2_38_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(00)00143-1"},{"key":"e_1_2_38_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.015"},{"key":"e_1_2_38_53_1","doi-asserted-by":"publisher","DOI":"10.1110\/ps.036012.108"},{"key":"e_1_2_38_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/30666"},{"key":"e_1_2_38_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2210-6-9"},{"key":"e_1_2_38_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03370-2"},{"key":"e_1_2_38_57_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M701790200"},{"key":"e_1_2_38_58_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4542-06.2007"},{"key":"e_1_2_38_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.12.028"},{"key":"e_1_2_38_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01215.x"},{"key":"e_1_2_38_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13081"},{"key":"e_1_2_38_62_1","first-page":"362","article-title":"Lasmiditan inhibits CGRP release in the mouse trigeminovascular system","volume":"37","author":"Labastida\u2010Ramirez A","year":"2017","journal-title":"Cephalalgia"},{"key":"e_1_2_38_63_1","first-page":"104","article-title":"Lasmiditan and sumatriptan: Comparison of in vivo vascular constriction in the dog and in vitro contraction of human arteries","volume":"36","author":"Rubio Beltran E","year":"2016","journal-title":"Cephalalgia"},{"issue":"2","key":"e_1_2_38_64_1","first-page":"64","article-title":"Lasmiditan Inhibits CGRP release in the mouse trigeminovascular system. Poster ORO3, also presented as ePoster","volume":"58","author":"Maasen van den Brink A","year":"2018","journal-title":"Headache"},{"key":"e_1_2_38_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412472072"},{"key":"e_1_2_38_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.5b02921"},{"key":"e_1_2_38_67_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109661200"},{"key":"e_1_2_38_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2010.05.014"},{"key":"e_1_2_38_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.11.076"},{"key":"e_1_2_38_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.07.005"},{"key":"e_1_2_38_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2017.02.001"},{"key":"e_1_2_38_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0490641"},{"key":"e_1_2_38_73_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.108.00372"},{"key":"e_1_2_38_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417691762"},{"key":"e_1_2_38_75_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398403"},{"key":"e_1_2_38_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm070668p"},{"key":"e_1_2_38_77_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.130344"},{"key":"e_1_2_38_78_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000286940.29755.61"},{"key":"e_1_2_38_79_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.206458"},{"key":"e_1_2_38_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2014.11.031"},{"key":"e_1_2_38_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12591"},{"key":"e_1_2_38_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww236"},{"key":"e_1_2_38_83_1","unstructured":"Alder Bio\u2010development Pipeline.Anti\u2010PACAP\u201038 antagonists (ALD 1910) for migraine prevention. Available at:http:\/\/www.alderbio.com\/therapeutics\/pipeline\/#ald403. Accessed February 24 2018."},{"key":"e_1_2_38_84_1","unstructured":"Amgen Bio\u2010development Pipeline.Study to evaluate the efficacy and safety of AMG 301 in migraine prevention. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03238781. Accessed February 24 2018."},{"key":"e_1_2_38_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2013.11.001"},{"key":"e_1_2_38_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1997.10"},{"key":"e_1_2_38_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03638-X"},{"key":"e_1_2_38_88_1","unstructured":"Available at:https:\/\/users.ox.ac.uk\/~path0116\/tig\/new1\/mabth.html. Accessed January 24 2018."},{"key":"e_1_2_38_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"e_1_2_38_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2008.06.006"},{"key":"e_1_2_38_91_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.70.12.3305"},{"key":"e_1_2_38_92_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1341029"},{"key":"e_1_2_38_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/2031352a0"},{"key":"e_1_2_38_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.9.1289"},{"key":"e_1_2_38_95_1","doi-asserted-by":"publisher","DOI":"10.1385\/IR:25:2:097"},{"key":"e_1_2_38_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01172-9"},{"key":"e_1_2_38_97_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.18.1.739"},{"key":"e_1_2_38_98_1","unstructured":"Available at:https:\/\/www.abcam.com\/protocols\/a-comparison-between-polyclonal-and-monoclonal. Accessed January 24 2018."},{"key":"e_1_2_38_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_2_38_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/321522a0"},{"key":"e_1_2_38_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/332323a0"},{"key":"e_1_2_38_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-7799(94)90139-2"},{"key":"e_1_2_38_103_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00495"},{"key":"e_1_2_38_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-931-0_7"},{"key":"e_1_2_38_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12179"},{"key":"e_1_2_38_106_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.743138"},{"key":"e_1_2_38_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"e_1_2_38_108_1","article-title":"Phase I, randomized, double\u2010blind, placebo\u2010controlled, single\u2010dose, and multiple\u2010dose studies of erenumab in healthy subjects and patients with migraine","author":"deHoon J","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_38_109_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200x.2000.01245.x"},{"key":"e_1_2_38_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1994.tb00873.x"},{"key":"e_1_2_38_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21105"},{"key":"e_1_2_38_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2014.05.004"},{"key":"e_1_2_38_113_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3859"},{"key":"e_1_2_38_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21147"},{"key":"e_1_2_38_115_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0674-4"},{"key":"e_1_2_38_116_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010510-100510"},{"key":"e_1_2_38_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1992.tb07084.x"},{"key":"e_1_2_38_118_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.057299"},{"key":"e_1_2_38_119_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_2_38_120_1","unstructured":"World Health Organization International Nonproprietary Names Information. Available at:https:\/\/apps.who.int\/medicinedocs\/en\/d\/Js23187en\/. Accessed December 15 2017."},{"key":"e_1_2_38_121_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00740"},{"key":"e_1_2_38_122_1","first-page":"1398 PS74LB","article-title":"Characterization of the intrinsic binding features of three anti\u2010CGRP therapeutic antibodies effective in preventing migraine: A comparative case study of ALD403, Ly\u20102951742, TEV\u201048125","volume":"56","author":"Latham J","year":"2016","journal-title":"Headache"},{"key":"e_1_2_38_123_1","unstructured":"Internal TEVA data 2017."},{"issue":"1","key":"e_1_2_38_124_1","first-page":"109 PO\u201001\u2010085","article-title":"Rational design of a monoclonal antibody inhibiting calcitonin gene\u2010related peptide, ALD403 (Eptinezumab), to provide early onset, high efficacy, extended duration of action, and desired safety for the prevention of migraine","volume":"37","author":"Baker B","year":"2017","journal-title":"Cephalalgia"},{"key":"e_1_2_38_125_1","unstructured":"Anton van der MerweP.Surface plasmon resonance. Available at:www.biophysics.bioc.cam.ac.uk\/wp-content\/uploads\/2011\/02\/spr1.pdf. Accessed February 2 2018."},{"key":"e_1_2_38_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2014.01.009"},{"key":"e_1_2_38_127_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.224212"},{"key":"e_1_2_38_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2005.01.001"},{"key":"e_1_2_38_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2005.01.004"},{"key":"e_1_2_38_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbt.2009.03.012"},{"key":"e_1_2_38_131_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2015.974545"},{"key":"e_1_2_38_132_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0811-5"},{"key":"e_1_2_38_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470292549.ch14"},{"key":"e_1_2_38_134_1","unstructured":"Food and Drug Administration.Assay development and validation for immunogenicity testing of therapeutic protein products. Guidance for industry. April 2016. Available at:https:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/UCM192750.pdf. Accessed February 10 2018."},{"key":"e_1_2_38_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70209-1"},{"key":"e_1_2_38_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"e_1_2_38_137_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_38_138_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004391"},{"key":"e_1_2_38_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00249-5"},{"key":"e_1_2_38_140_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_38_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70128-0"},{"key":"e_1_2_38_142_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417747230"},{"key":"e_1_2_38_143_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0659-0"},{"key":"e_1_2_38_144_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1104650"},{"key":"e_1_2_38_145_1","first-page":"50","volume-title":"Group Processes","author":"Luft J","year":"1963"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.13432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:34:15Z","timestamp":1762079655000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,3]]},"references-count":144,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/head.13432"],"URL":"https:\/\/doi.org\/10.1111\/head.13432","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"type":"print","value":"0017-8748"},{"type":"electronic","value":"1526-4610"}],"subject":[],"published":{"date-parts":[[2018,11,3]]},"assertion":[{"value":"2018-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}